Overview
A randomised control study of metformin in people with mild cognitive impairment and without diabetes mellitus to determine effects on cognitive decline and neuroimaging over 3 years.
Description
A randomised placebo-control study of metformin in people with mild cognitive impairment and without diabetes mellitus to determine effects on cognitive decline, neuroimaging and biomarkers over 3 years.
Eligibility
Inclusion Criteria:
- overweight or obese (body mass index >25.0 kg/m2, waist: women>80 cm, men>94cm;
- Mild cognitive impairment (Mild Neurocognitive Disorder), based on DSM-5 criteria;
- Fasting blood glucose <7.0 mmol/L and HbA1c <6.5%;
- Able to undertake neurocognitive testing in English.
- Not participating in another trial of drugs or lifestyle modification to reduce cognitive decline.
Exclusion Criteria:
- Life-threatening illnesses to preclude participation in a 3-year study;
- Contraindications to the use of metformin (severe heart failure or eGFR <40).